Atea Pharmaceuticals (AVIR)
Develops oral antiviral candidates for HCV and HEV infections.
$5.73
Pre-market+0.03 (+0.44%)
At close$5.71(+3.92%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions127 holders · as of Jun 30, 2026 | 75.74% | 60.74M shares | |
| Insiders13 holders · as of Jun 23, 2026 | 10.84% | 8.70M shares | |
| Otherremainder | 13.42% | 10.76M shares |
80.20M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutions13F, as of Jun 30, 2026
127 holders · 60.74M shares · 20 new positions · 67 increased · 37 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 12.00M | 14.97% | +53.3K | Aug 13, 2026 |
| BlackRock, Inc. | 8.72M | 10.87% | +284.6K | Aug 7, 2026 |
| BML Capital Management, LLC | 6.95M | 8.67% | −106.3K | Aug 7, 2026 |
| Tang Capital Management LLC | 4.81M | 6.00% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.96M | 3.70% | −281.3K | Aug 13, 2026 |
| Bain Capital Life Sciences Investors, LLC | 2.08M | 2.59% | −285.0K | Aug 14, 2026 |
| Acadian Asset Management LLC | 2.04M | 2.54% | +452.4K | Aug 13, 2026 |
| Geode Capital Management, LLC | 1.96M | 2.44% | +210.7K | Aug 12, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 11.95M | 13G | May 6, 2026 ↗ |
| BML Investment Partners, L.P. | 9.60% | 7.49M | 13G | Feb 9, 2026 ↗ |
| BlackRock, Inc. | 7.10% | 6.08M | 13G | Apr 23, 2025 ↗ |
| JPM Partners LLC | 6.90% | 5.87M | 13G | May 14, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 18, 2026 | Polly A. Murphydirector | Purchase | 6,100 | $4.17 | 92,145 |
| May 18, 2025 | Polly A. Murphydirector | Purchase | 6,100 | $4.17 | 92,145 |
CongressHouse and Senate disclosures
Not reported.
